Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646230 · ClinicalTrials.gov registry record · Phase 1
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
A Phase 1 study of Neuroblastoma, sponsored by Nant Operations Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 13
- Study locations
NCT00646230: Completed Phase 1 study of Neuroblastoma, sponsored by Nant Operations Center.
NCT00646230 is a Phase 1 study of Neuroblastoma that has completed, run by Nant Operations Center. The registered enrollment target is 17 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00646230, a Phase 1 study of Neuroblastoma, has completed, sponsored by Nant Operations Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma.
Primary Outcome
Adverse events, clinically significant changes in lab results or vitals will be captured throughout the duration of the study.
Conditions Studied
Interventions
- OTHER pharmacological study
- OTHER high performance liquid chromatography
- DRUG fenretinide
Study Locations (13)
California
- Childrens Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Texas
- Cook Children's Medical Center - Fort Worth - Fort Worth
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital - Houston
Georgia
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus - Atlanta
Illinois
- University of Chicago Comer Children's Hospital - Chicago
Massachusetts
- Children's Hospital Boston - Boston
Michigan
- C.S. Mott Children's Hospital at University of Michigan Medical Center - Ann Arbor
New York
- Morgan Stanley Children's Hospital of New York-Presbyterian - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT00646230 record still lists
NCT00646230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which pharmacological study is the first listed.
NCT00646230 lists 13 locations in 10 states (California, Texas, Georgia).
Frequently Asked Questions
What is clinical trial NCT00646230 about?
NCT00646230 is a clinical study titled "N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma". RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young pa...
What is the current status of trial NCT00646230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2006-12. Estimated completion is 2012-03.
What conditions does trial NCT00646230 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00646230?
The interventions under investigation include: pharmacological study (OTHER), high performance liquid chromatography (OTHER), fenretinide (DRUG).
Who is sponsoring clinical trial NCT00646230?
This trial is sponsored by Nant Operations Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00646230 being conducted?
This trial has 13 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00646230's enrollment target sits among peer trials
17 82nd of 94 higher than 13 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia